Linagliptin [linagliptin]
topical
36
- Terms
-
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-
BI 1356
BI-1356
BI1356
Tradjenta
Trajenta
Persistent link
https://www.medvik.cz/link/D000069476
Definition
A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.
- DUI
- D000069476 MeSH Browser
- CUI
- M0554626
- History note
- 2016 (2011)
- Public note
- 2016; LINAGLIPTIN was indexed under PURINES and QUINAZOLINES 2011-2015
Allowable subheadings
- AD
- administration & dosage 14
- AE
- adverse effects 10
- AG
- agonists
- AA
- analogs & derivatives
- AN
- analysis
- AI
- antagonists & inhibitors
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry 1
- CL
- classification
- EC
- economics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 3
- PD
- pharmacology 7
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 18
- TO
- toxicity
- UR
- urine
...
Occurrences in Medvik records